Analysts Anticipate Spero Therapeutics Inc (SPRO) Will Announce Earnings of -$1.56 Per Share

Wall Street analysts expect that Spero Therapeutics Inc (NASDAQ:SPRO) will post earnings of ($1.56) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Spero Therapeutics’ earnings, with the highest EPS estimate coming in at ($1.22) and the lowest estimate coming in at ($1.89). The business is scheduled to issue its next quarterly earnings report on Thursday, March 8th.

According to Zacks, analysts expect that Spero Therapeutics will report full-year earnings of ($8.53) per share for the current financial year, with EPS estimates ranging from ($13.40) to ($3.88). For the next financial year, analysts forecast that the company will post earnings of ($5.21) per share, with EPS estimates ranging from ($7.75) to ($3.11). Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for Spero Therapeutics.

Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings data on Thursday, December 14th. The company reported ($36.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.43) by ($33.59). The company had revenue of $0.60 million for the quarter, compared to analyst estimates of $0.20 million.

Several equities analysts have recently weighed in on SPRO shares. Oppenheimer started coverage on shares of Spero Therapeutics in a research note on Monday, November 27th. They issued a “buy” rating and a $30.00 target price for the company. Cowen started coverage on shares of Spero Therapeutics in a research note on Monday, November 27th. They issued an “outperform” rating for the company. Stifel Nicolaus started coverage on shares of Spero Therapeutics in a research note on Monday, November 27th. They issued a “buy” rating and a $26.00 target price for the company. Bank of America started coverage on shares of Spero Therapeutics in a research note on Monday, November 27th. They issued a “neutral” rating for the company. Finally, Zacks Investment Research upgraded shares of Spero Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Tuesday, January 30th. Two analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $24.25.

Spero Therapeutics (NASDAQ:SPRO) opened at $10.03 on Wednesday. Spero Therapeutics has a 12 month low of $9.66 and a 12 month high of $15.40.

A number of large investors have recently modified their holdings of SPRO. Atlas Venture Associates IX LLC purchased a new position in Spero Therapeutics during the fourth quarter valued at approximately $16,179,000. BVF Inc. IL purchased a new position in Spero Therapeutics during the fourth quarter valued at approximately $12,093,000. Rock Springs Capital Management LP purchased a new position in Spero Therapeutics during the fourth quarter valued at approximately $6,169,000. VHCP Management II LLC purchased a new position in Spero Therapeutics during the fourth quarter valued at approximately $5,706,000. Finally, AWM Investment Company Inc. purchased a new position in Spero Therapeutics during the fourth quarter valued at approximately $4,112,000. 25.54% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Analysts Anticipate Spero Therapeutics Inc (SPRO) Will Announce Earnings of -$1.56 Per Share” was first posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.thelincolnianonline.com/2018/02/21/analysts-anticipate-spero-therapeutics-inc-spro-will-announce-earnings-of-1-56-per-share.html.

About Spero Therapeutics

Spero Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. The Company is developing a portfolio of novel product candidates, including SPR994, Potentiator Platform (SPR741 and SPR206), and SPR720.

Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply